Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
BOSTON, April 18, 2017 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Thursday, May 4, 2017 at 8:00 a.m. ET to discuss its first quarter 2017 financial results and provide corporate updates.
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 8810002. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617.466.3511 [email protected]
